Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.
![Johnson & Johnson logo](/files/LOGO/200406-JNJ.png)
Company profile
Ticker
JNJ
Exchange
Website
CEO
Alex Gorsky
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
JOHNSON & JOHNSON ET AL
SEC CIK
Corporate docs
Subsidiaries
ABD Holding Company, Inc. • ABIOMED COMMERCIAL, LLC • ABIOMED R&D, Inc. • ABIOMED, Inc. • Acclarent, Inc. • Actelion Pharmaceuticals US, Inc. • Albany Street LLC • ALZA Corporation • Alza Land Management, Inc. • AMO Development, LLC ...
IRS number
221024240
JNJ stock data
Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
25 Jul 24
8-K
Johnson & Johnson reports Q2 2024 results
17 Jul 24
SD
Conflict minerals disclosure
28 May 24
CERT
Certification of approval for exchange listing
21 May 24
8-A12B
Registration of securities on exchange
20 May 24
8-K
Other Events
20 May 24
25-NSE
Exchange delisting
20 May 24
8-K
Other Events
17 May 24
424B2
Prospectus for primary offering
16 May 24
FWP
Free writing prospectus
14 May 24
Transcripts
JNJ
Earnings call transcript
2024 Q2
17 Jul 24
JNJ
Earnings call transcript
2024 Q1
16 Apr 24
JNJ
Earnings call transcript
2023 Q4
23 Jan 24
JNJ
Earnings call transcript
2023 Q3
17 Oct 23
JNJ
Earnings call transcript
2023 Q2
20 Jul 23
JNJ
Earnings call transcript
2023 Q2
20 Jul 23
JNJ
Earnings call transcript
2023 Q1
18 Apr 23
JNJ
Earnings call transcript
2022 Q4
24 Jan 23
JNJ
Earnings call transcript
2022 Q3
18 Oct 22
JNJ
Earnings call transcript
2022 Q2
19 Jul 22
Latest ownership filings
4
Vanessa Broadhurst
9 Jul 24
11-K/A
Annual report of employee stock purchases (amended)
25 Jun 24
11-K
Annual report of employee stock purchases
24 Jun 24
11-K
Annual report of employee stock purchases
24 Jun 24
4
Eugene A. Woods
6 Jun 24
4
MARILLYN A HEWSON
6 Jun 24
SC 13G/A
Kenvue Inc.
20 May 24
13F-HR
Quarterly holdings report by institutional manager
10 May 24
4
JOHN C REED
3 May 24
4
Mary C Beckerle
29 Apr 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Oct 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Jan 23 | Jan 22 | Jan 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 24.88 bn | 24.88 bn | 24.88 bn | 24.88 bn | 24.88 bn | 24.88 bn |
Cash burn (monthly) | 198.33 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 178.38 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 24.70 bn | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 124.5 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2024
67.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3668 |
Opened positions | 564 |
Closed positions | 219 |
Increased positions | 1318 |
Reduced positions | 1465 |
13F shares | Current |
---|---|
Total value | 240.75 tn |
Total shares | 1.63 bn |
Total puts | 11.82 mm |
Total calls | 14.57 mm |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 228.94 mm | $36.22 tn |
BLK Blackrock | 189.73 mm | $30.01 tn |
STT State Street | 133.52 mm | $21.12 tn |
Geode Capital Management | 53.32 mm | $8.42 tn |
MS Morgan Stanley | 42.55 mm | $6.73 tn |
State Farm Mutual Automobile Insurance | 31.68 mm | $5.01 tn |
JPM JPMorgan Chase & Co. | 29.85 mm | $4.72 tn |
NTRS Northern Trust | 28.63 mm | $4.53 tn |
Wellington Management | 23.75 mm | $3.76 tn |
BAC Bank Of America | 23.72 mm | $3.75 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Jul 24 | Vanessa Broadhurst | Common Stock | Payment of exercise | Dispose F | No | No | 147.16 | 5,018 | 738.45 k | 19,834 |
8 Jul 24 | Vanessa Broadhurst | Common Stock | Option exercise | Acquire M | No | No | 0 | 9,809 | 0.00 | 24,852 |
8 Jul 24 | Vanessa Broadhurst | Restricted Share Units Common Stock | Option exercise | Dispose M | No | No | 0 | 9,809 | 0.00 | 0 |
4 Jun 24 | Woods Eugene A. | Deferred Share Units Common Stock | Grant | Acquire A | No | No | 147.85 | 211.363 | 31.25 k | 2,368.446 |
4 Jun 24 | Marillyn A Hewson | Deferred Share Units Common Stock | Grant | Acquire A | No | No | 147.85 | 314.618 | 46.52 k | 10,573.383 |
1 May 24 | John C Reed | Common Stock | Payment of exercise | Dispose F | No | No | 144.59 | 10,984 | 1.59 mm | 11,577 |
1 May 24 | John C Reed | Common Stock | Option exercise | Acquire M | No | No | 0 | 22,255 | 0.00 | 22,561 |
1 May 24 | John C Reed | Restricted Share Units Common Stock | Option exercise | Dispose M | No | No | 0 | 22,255 | 0.00 | 53,510 |
25 Apr 24 | Joly Hubert | Deferred Share Units Common Stock | Grant | Acquire A | No | No | 0 | 1,385.697 | 0.00 | 6,464.145 |
News
10 Health Care Stocks Whale Activity In Today's Session
26 Jul 24
Courts, Congress Likely To Stand In Way Of J&J's Third Texas Two-Step Plan; U.S. Court Of Appeals For 3rd Circuit Latest To Reject Unprecedented Bankruptcy Strategy; Lawyers On Behalf Of Ovarian Cancer Victims Are Calling On Johnson & Johnson To End Its "War Of Attrition Against Cancer Victims."
26 Jul 24
Looking Into Johnson & Johnson's Recent Short Interest
25 Jul 24
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
24 Jul 24
Check Out What Whales Are Doing With JNJ
24 Jul 24
Press releases
Courts, Congress Likely to Stand in Way of J&J's Third Texas Two-Step Plan
26 Jul 24
FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan
26 Jul 24
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
23 Jul 24
Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J's Latest Bankruptcy Plan
22 Jul 24
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
22 Jul 24